Login to Your Account

RTF Letter a 'Hiccup'

Gilead 4Q Results, HIV Drug Outlook Encourage Analysts

By Tom Wall

Thursday, January 27, 2011
Calling it a "temporary setback," "easily remedied" and "relatively immaterial," analysts played down the negative impact of the FDA's refuse-to-file (RTF) letter to Gilead Sciences Inc. for its new drug application (NDA) seeking approval of HIV single-tablet regimen Truvada (emtricitabine/tenofovir disoproxil fumarate) plus Tibotec Pharmaceuticals Ltd.'s TMC278 (rilpivirine).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription